The Biostatistics and Informatics Core for the Duke SPORE in Brain Cancer supports the statistical, bioinformatics and information systems needs of all projects and cores in the SPORE. The Core was developed as a collaboration between Cancer Center Biostatistics and Cancer Center Information Systems (CCIS). Dr. Stephen L. George, Ph.D., Director of Cancer Center Biostatistics and Group Statistician for the CALGB and Kimberly Johnson, Director of Cancer Center Information Systems are Co-Directors of the Core. Dr. George will direct biostatistics and bioinformatics initiatives in this area, while Ms. Johnson will direct information systems initiatives and assist Dr. George in administering the Core. CCIS falls under the administrative oversight of Dr. George within the Cancer Center. Additional staff for this Core includes statisticians and programmers dedicated to each project and core based on their area of expertise and past associations with individual projects. In addition to the core directors, partial support is requested for three statistical personnel (.70 FTE total), one bioinformatician (.10 FTE), two information systems personnel (.55 FTE total) and one full-time data manager. This Core will provide assistance in the statistical analysis of clinical, pre-clinical and laboratory studies, as well as genetic investigations. In addition, the Core will support the development of research database structures and data management activities. The Core will use existing computing infrastructure resources as an efficient means to support SPORE research and will build on past successes in infrastructure development. Resources available to this Core include 25 servers supported by CCIS, offering over 20GB of memory and 2 TB of disk space with multi-processing capabilities and a variety of software applications and compilers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA108786-01
Application #
6844185
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Project Start
2004-07-01
Project End
2009-06-30
Budget Start
2004-07-01
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$210,410
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Lock, Richard; Carol, Hernan; Maris, John M et al. (2017) Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64:
Kurmasheva, Raushan T; Sammons, Melissa; Favours, Edward et al. (2017) Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
Kurmasheva, Raushan T; Gorlick, Richard; Kolb, E Anders et al. (2017) Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
Kang, Min H; Reynolds, C Patrick; Kolb, E Anders et al. (2016) Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:1744-52
Attiyeh, Edward F; Maris, John M; Lock, Richard et al. (2016) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63:276-86
Gorlick, Richard; Kolb, E Anders; Keir, Stephen T et al. (2016) Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 63:443-50
Smith, Malcolm A; Hampton, Oliver A; Reynolds, C Patrick et al. (2015) Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 62:91-8
Krishnamachari, Bhuma; Il'yasova, Dora; Scheurer, Michael E et al. (2015) A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups. Ann Epidemiol 25:270-4
Sayour, Elias J; McLendon, Pat; McLendon, Roger et al. (2015) Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64:419-27

Showing the most recent 10 out of 178 publications